Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Oncology Pipeline Has Three Potential Blockbusters In The Offing

Executive Summary

Novartis is aiming to launch a trio of potential blockbuster oncology drugs in the next few years that the firm hopes will erase the memory of several recent high-profile setbacks in multiple therapeutic areas

You may also be interested in...



Novartis’ Tasigna Joins Bristol’s Sprycel For CML Resistant To Gleevec

Novartis expects Tasigna (nilotinib) will be used in the small number of chronic myeloid leukemia patients with advanced resistant disease who already have received high dose Gleevec (imatinib), and as a result, is pricing the product on par with the 800 mg dose of Gleevec typically used for such patients - about $5,700 per month

Novartis’ Tasigna Joins Bristol’s Sprycel For CML Resistant To Gleevec

Novartis expects Tasigna (nilotinib) will be used in the small number of chronic myeloid leukemia patients with advanced resistant disease who already have received high dose Gleevec (imatinib), and as a result, is pricing the product on par with the 800 mg dose of Gleevec typically used for such patients - about $5,700 per month

Prexige “not approvable”

Novartis receives a "not approvable" letter from FDA for its COX-2 inhibitor lumiracoxib for osteoarthritic pain, firm announces Sept. 27. The negative outcome is not unexpected as CEO Daniel Vasella previously told analysts, "I don't think we will get an approval" (1"The Pink Sheet" Sept. 17, 2007, p. 11). Novartis is not completely abandoning hope that Prexige could be approved for specific populations, such as patients with a higher incidence of gastrointestinal complications, including those suffering from ulcers or being treated with anticoagulants...

Related Content

UsernamePublicRestriction

Register

MT142313

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel